Catalent Inc Expected to Earn Q2 2017 Earnings of $0.24 Per Share (CTLT)
Catalent Inc (NASDAQ:CTLT) – Equities researchers at KeyCorp lowered their Q2 2017 earnings per share (EPS) estimates for Catalent in a research report issued on Monday. KeyCorp analyst M. Mishan now anticipates that the brokerage will post earnings per share of $0.24 for the quarter, down from their prior forecast of $0.29. KeyCorp currently has a “Overweight” rating and a $29.00 target price on the stock. KeyCorp also issued estimates for Catalent’s Q3 2017 earnings at $0.35 EPS and Q4 2017 earnings at $0.58 EPS.
CTLT has been the subject of several other reports. Piper Jaffray Cos. reissued an “overweight” rating and set a $30.00 price objective (down from $30.50) on shares of Catalent in a report on Tuesday, August 30th. Jefferies Group reaffirmed a “hold” rating and set a $25.00 target price on shares of Catalent in a report on Tuesday, August 30th. Morgan Stanley reaffirmed a “hold” rating on shares of Catalent in a report on Tuesday, August 30th. Stephens assumed coverage on shares of Catalent in a report on Tuesday, October 18th. They set an “overweight” rating and a $31.00 target price for the company. Finally, TheStreet raised shares of Catalent from a “sell” rating to a “hold” rating in a report on Wednesday, August 17th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. Catalent currently has a consensus rating of “Hold” and an average price target of $28.67.
Shares of Catalent (NASDAQ:CTLT) opened at 25.33 on Thursday. Catalent has a 52-week low of $18.92 and a 52-week high of $32.24. The stock’s 50 day moving average is $24.48 and its 200 day moving average is $24.93. The stock has a market cap of $3.16 billion and a PE ratio of 30.34.
Catalent (NASDAQ:CTLT) last announced its quarterly earnings results on Monday, November 7th. The company reported $0.16 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.01. The firm earned $442.20 million during the quarter, compared to the consensus estimate of $430.26 million. During the same period in the previous year, the business earned $0.18 earnings per share. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis.
In other Catalent news, major shareholder Blackstone Management Associat sold 17,100,705 shares of the company’s stock in a transaction that occurred on Friday, September 9th. The shares were sold at an average price of $23.58, for a total value of $403,234,623.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Several institutional investors have recently modified their holdings of CTLT. FMR LLC raised its position in shares of Catalent by 89.1% in the second quarter. FMR LLC now owns 14,597,087 shares of the company’s stock worth $335,587,000 after buying an additional 6,877,549 shares in the last quarter. Laurion Capital Management LP raised its position in shares of Catalent by 323.0% in the third quarter. Laurion Capital Management LP now owns 2,005,074 shares of the company’s stock worth $51,811,000 after buying an additional 1,531,074 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Catalent by 15.2% in the second quarter. Vanguard Group Inc. now owns 7,881,737 shares of the company’s stock worth $181,201,000 after buying an additional 1,039,117 shares in the last quarter. BlackRock Fund Advisors raised its position in shares of Catalent by 15.0% in the third quarter. BlackRock Fund Advisors now owns 6,579,877 shares of the company’s stock worth $170,024,000 after buying an additional 858,781 shares in the last quarter. Finally, UBS Asset Management Americas Inc. raised its position in shares of Catalent by 23.2% in the second quarter. UBS Asset Management Americas Inc. now owns 4,252,650 shares of the company’s stock worth $97,768,000 after buying an additional 799,498 shares in the last quarter.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Stock Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related stocks with our FREE daily email newsletter.